Cytosorbents Corporation

NasdaqCM:CTSO Voorraadrapport

Marktkapitalisatie: US$48.7m

Cytosorbents Beheer

Beheer criteriumcontroles 2/4

De CEO Cytosorbents is Phil Chan, benoemd in Jan2009, heeft een ambtstermijn van 15.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.33M, bestaande uit 36.2% salaris en 63.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.35% van de aandelen van het bedrijf, ter waarde $ 658.04K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.5 jaar en 10.2 jaar.

Belangrijke informatie

Phil Chan

Algemeen directeur

US$1.3m

Totale compensatie

Percentage CEO-salaris36.2%
Dienstverband CEO15.8yrs
Eigendom CEO1.4%
Management gemiddelde ambtstermijn4.5yrs
Gemiddelde ambtstermijn bestuur10.2yrs

Recente managementupdates

Recent updates

The Market Lifts Cytosorbents Corporation (NASDAQ:CTSO) Shares 43% But It Can Do More

Oct 01
The Market Lifts Cytosorbents Corporation (NASDAQ:CTSO) Shares 43% But It Can Do More

Investors Continue Waiting On Sidelines For Cytosorbents Corporation (NASDAQ:CTSO)

Jul 04
Investors Continue Waiting On Sidelines For Cytosorbents Corporation (NASDAQ:CTSO)

Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?

Mar 16
Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?

Take Care Before Jumping Onto Cytosorbents Corporation (NASDAQ:CTSO) Even Though It's 28% Cheaper

Jan 06
Take Care Before Jumping Onto Cytosorbents Corporation (NASDAQ:CTSO) Even Though It's 28% Cheaper

Is Cytosorbents (NASDAQ:CTSO) Using Too Much Debt?

Nov 10
Is Cytosorbents (NASDAQ:CTSO) Using Too Much Debt?

Shareholders Should Be Pleased With Cytosorbents Corporation's (NASDAQ:CTSO) Price

Jul 13
Shareholders Should Be Pleased With Cytosorbents Corporation's (NASDAQ:CTSO) Price

Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?

May 16
Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?

We're A Little Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate

Mar 08
We're A Little Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate

CytoSorbents secures $4.3M contract by U.S. Department of Defense

Oct 06

CytoSorbents stock rises on US DoD contract to develop device for universal plasma

Sep 09

We're A Little Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate

Sep 02
We're A Little Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate

CytoSorbents gets reimbursement for CytoSorb in Turkey

Aug 23

CytoSorbents stock rises 10% as Israel approves coverage for CytoSorb system

Aug 17

Cytosorbents GAAP EPS of -$0.25 misses by $0.13, revenue of $8.5M misses by $1.06M

Aug 02

Analyse CEO-vergoeding

Hoe is Phil Chan's beloning veranderd ten opzichte van Cytosorbents's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

-US$19m

Jun 30 2024n/an/a

-US$26m

Mar 31 2024n/an/a

-US$28m

Dec 31 2023US$1mUS$483k

-US$29m

Sep 30 2023n/an/a

-US$23m

Jun 30 2023n/an/a

-US$26m

Mar 31 2023n/an/a

-US$31m

Dec 31 2022US$1mUS$483k

-US$33m

Sep 30 2022n/an/a

-US$41m

Jun 30 2022n/an/a

-US$36m

Mar 31 2022n/an/a

-US$29m

Dec 31 2021US$2mUS$483k

-US$25m

Sep 30 2021n/an/a

-US$16m

Jun 30 2021n/an/a

-US$10m

Mar 31 2021n/an/a

-US$9m

Dec 31 2020US$1mUS$456k

-US$8m

Sep 30 2020n/an/a

-US$11m

Jun 30 2020n/an/a

-US$17m

Mar 31 2020n/an/a

-US$18m

Dec 31 2019US$1mUS$438k

-US$19m

Sep 30 2019n/an/a

-US$21m

Jun 30 2019n/an/a

-US$17m

Mar 31 2019n/an/a

-US$19m

Dec 31 2018US$1mUS$400k

-US$17m

Sep 30 2018n/an/a

-US$15m

Jun 30 2018n/an/a

-US$14m

Mar 31 2018n/an/a

-US$10m

Dec 31 2017US$828kUS$378k

-US$9m

Compensatie versus markt: De totale vergoeding ($USD 1.33M ) Phil } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 652.28K ).

Compensatie versus inkomsten: De vergoeding van Phil is gestegen terwijl het bedrijf verliesgevend is.


CEO

Phil Chan (54 yo)

15.8yrs

Tenure

US$1,333,402

Compensatie

Dr. Phillip P. Chan, M.D., Ph D., is known as Phil has been the Chief Executive Officer at Cytosorbents Corporation since January 2009 and served as its President until May 2020. Dr. Chan serves as a Partn...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Phillip Chan
CEO & Director15.8yrsUS$1.33m1.35%
$ 658.0k
Vincent Capponi
President & COO19.3yrsUS$1.11m0.51%
$ 250.2k
Kathleen Bloch
Advisorless than a yearUS$816.08k0.54%
$ 262.5k
Efthymios Deliargyris
Chief Medical Officer4.5yrsUS$1.06m0.17%
$ 83.6k
Peter Mariani
Chief Financial Officerless than a yeargeen gegevensgeen gegevens
Terri Powers
Vice President of Investor Relations & Corporate Communications3.4yrsgeen gegevensgeen gegevens
Christian Steiner
Executive Vice President of Sales & Marketing12.4yrsgeen gegevensgeen gegevens
Christopher Cramer
Senior Vice President of Business Development1.8yrsgeen gegevensgeen gegevens
Jodi Hoover
Executiveno datageen gegevensgeen gegevens
Robert Bartlett
Co-Chairman of Cardiac Surgery Advisory Board & Consultant7.4yrsUS$97.32kgeen gegevens

4.5yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van CTSO wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.5 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Phillip Chan
CEO & Director16.3yrsUS$1.33m1.35%
$ 658.0k
Robert Bartlett
Co-Chairman of Cardiac Surgery Advisory Board & Consultant10.2yrsUS$97.32kgeen gegevens
Claudio Ronco
Member of Critical Care Advisory Boardno datageen gegevensgeen gegevens
Alan Sobel
Independent Director10yrsUS$118.47k0.063%
$ 30.8k
Edward Jones
Independent Director17.6yrsUS$101.93k0.036%
$ 17.4k
Joseph Parrillo
Member of Critical Care Advisory Boardno datageen gegevensgeen gegevens
Ronald Maier
Chairman of the Trauma Advisory Board11.6yrsgeen gegevensgeen gegevens
Mitchell Cohen
Member of Trauma Advisory Boardno datageen gegevensgeen gegevens
Ernest Moore
Member of Trauma Advisory Board11.6yrsgeen gegevensgeen gegevens
Joseph Zwischenberger
Chairman of Cardiac Surgery Advisory Board10.2yrsgeen gegevensgeen gegevens
Jonathan Haft
Member of Cardiac Surgery Advisory Board10.2yrsgeen gegevensgeen gegevens
Michael Bator
Independent Chairman of the Board9.3yrsUS$161.70k0.10%
$ 49.9k

10.2yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van CTSO zijn ervaren en ervaren (gemiddelde ambtstermijn van 10.2 jaar).